Stock COLL COLLEGIUM PHARMACEUTICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
33.14 USD +2.19% Intraday chart for Collegium Pharmaceutical, Inc. -3.24% +7.67%
May. 13 Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program MT
May. 10 Needham Downgrades Collegium Pharmaceutical to Hold From Buy MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Collegium to Participate in Jefferies Global Healthcare Conference
GL
Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program
MT
Collegium Announces $35 Million Accelerated Share Repurchase Program
GL
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024
AQ
Needham Downgrades Collegium Pharmaceutical to Hold From Buy
MT
Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39
MT
Collegium Pharmaceutical Q1 Adjusted Net Income, Revenue Rise; 2024 Outlook Reiterated
MT
Collegium Pharmaceutical: Q1 Earnings Snapshot
AQ
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q1 EPS $1.45, vs. Street Est of $1.47
MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024
CI
Transcript : Collegium Pharmaceutical, Inc., Q1 2024 Earnings Call, May 09, 2024
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 3, 2024.
CI
Collegium Reports First Quarter 2024 Financial Results
GL
Collegium Announces CEO Transition
GL
Collegium Announces CEO Transition
CI
Collegium Announces President and Board Changes
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
PTAB's Authority To Issue A Final Written Decision After A Statutory Deadline
AQ
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
GL
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COLL Stock
  4. News Collegium Pharmaceutical, Inc.